Metastatic Renal Cell Cancer - Pipeline Review, H1 2013


#168390

37pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, 'Metastatic Renal Cell Cancer Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Renal Cell Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Renal Cell Cancer. 

Metastatic Renal Cell Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Metastatic Renal Cell Cancer.
  • A review of the Metastatic Renal Cell Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Renal Cell Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Metastatic Renal Cell Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Renal Cell Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Metastatic Renal Cell Cancer Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Metastatic Renal Cell Cancer 6
Metastatic Renal Cell Cancer Therapeutics under Development by Companies 8
Metastatic Renal Cell Cancer Therapeutics under Investigation by Universities/Institutes 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Metastatic Renal Cell Cancer Therapeutics - Products under Development by Companies 12
Metastatic Renal Cell Cancer Therapeutics - Products under Investigation by Universities/Institutes 13
Companies Involved in Metastatic Renal Cell Cancer Therapeutics Development 14
Novartis AG 14
Astellas Pharma Inc. 15
Metastatic Renal Cell Cancer - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Combination Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
everolimus - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
AGS-16M8F - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Anti-NY ESO-1 TCR-Gene Engineered Autologous Lymphocytes + [aldesleukin] + [cyclophosphamide] + [fludarabine phosphate] - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Metastatic Renal Cell Cancer Therapeutics - Drug Profile Updates 27
Metastatic Renal Cell Cancer Therapeutics - Dormant Products 32
Metastatic Renal Cell Cancer - Product Development Milestones 33
Featured News & Press Releases 33
Sep 20, 2012: Aveo Oncology To Present New Clinical Data On Tivozanib At ESMO 2012 Congress 33
Jun 01, 2012: Bionomics To Present Clinical Trial Data Of BNC105 At ASCO Meeting 33
May 29, 2009: Bayer Schering Pharma To Present Data on Oncology Development Compound BAY 73-4506 34

Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37

Number of Products Under Development for Metastatic Renal Cell Cancer, H1 2013 6
Products under Development for Metastatic Renal Cell Cancer - Comparative Analysis, H1 2013 7
Number of Products under Development by Companies, H1 2013 8
Number of Products under Investigation by Universities/Institutes, H1 2013 9
Comparative Analysis by Mid Clinical Stage Development, H1 2013 10
Comparative Analysis by Early Clinical Stage Development, H1 2013 11
Products under Development by Companies, H1 2013 12
Products under Investigation by Universities/Institutes, H1 2013 13
Novartis AG, H1 2013 14
Astellas Pharma Inc., H1 2013 15
Assessment by Monotherapy Products, H1 2013 16
Assessment by Combination Products, H1 2013 17
Assessment by Stage and Route of Administration, H1 2013 19
Assessment by Stage and Molecule Type, H1 2013 21
Metastatic Renal Cell Cancer Therapeutics - Drug Profile Updates 27
Metastatic Renal Cell Cancer Therapeutics - Dormant Products 32
Number of Products under Development for Metastatic Renal Cell Cancer, H1 2013 6
Products under Development for Metastatic Renal Cell Cancer - Comparative Analysis, H1 2013 7
Products under Development by Companies, H1 2013 8
Products under Investigation by Universities/Institutes, H1 2013 9
Mid Clinical Stage Products, H1 2013 10
Early Clinical Stage Products, H1 2013 11
Assessment by Monotherapy Products, H1 2013 16
Assessment by Combination Products, H1 2013 17
Assessment by Route of Administration, H1 2013 18
Assessment by Stage and Route of Administration, H1 2013 19
Assessment by Molecule Type, H1 2013 20
Assessment by Stage and Molecule Type, H1 2013 21